Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Harvard Business School
Deloitte
Daiichi Sankyo
Fuji
Medtronic
Healthtrust
US Department of Justice
Johnson and Johnson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,283,233

« Back to Dashboard

Which drugs does patent 9,283,233 protect, and when does it expire?

Patent 9,283,233 protects ELLA and is included in one NDA.

This patent has twenty-three patent family members in twenty-three countries.
Summary for Patent: 9,283,233
Title:Method for on-demand contraception
Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-- dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
Inventor(s): Ulmann; Andre (Paris, FR), Gainer; Erin (Chardonne, CH), Mathe; Henri Camille (Paris, FR), Blithe; Diana (Silver Spring, MD), Nieman; Lynnette (Bethesda, MD)
Assignee: LABORATOIRE HRA-PHARMA (Paris, FR) The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:14/635,107
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,283,233
Patent Claim Types:
see list of patent claims
Use; Dosage form; Formulation;

Drugs Protected by US Patent 9,283,233

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,283,233

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,616,073 Method for on-demand contraception ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,283,233

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2419108 ➤ Try a Free Trial
Russian Federation 2542779 ➤ Try a Free Trial
Russian Federation 2011146058 ➤ Try a Free Trial
Serbia 55331 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Dow
Medtronic
Covington
Teva
Accenture
Chubb
Johnson and Johnson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.